2024 Repligen corp stock - WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch ...

 
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments.. Repligen corp stock

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corporation Common Stock (RGEN) Stock Price, Quote, News & History | Nasdaq MY QUOTES: RGEN Edit my quotes Repligen Corporation Common Stock (RGEN) 0 Add to Watchlist...Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 12.34% in the past year. Currently, Repligen Corp’s price-earnings ratio is 74.0. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Dec 4, 2023 · × Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGE Repligen Corporation (NasdaqGS:RGEN) completed the acquisition of Bio-Flex Solutions, L.L.C. / Newton T & M Corp for $31.8 million on December 16, 2021. The purchase price of $31.8 million includes $3 million deposited into an escrow against which the Company may make claims for indemnification.Nov 30, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. Feb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%. On October 17, 2023, Repligen Corp (RGEN) stock showed promising performances, with a median target price forecast of $195.00 by 13 analysts. This represents a potential increase of 33.96% from the last recorded price of $145.57. The high estimate for the stock price is $240.00, while the low estimate is $165.00.Currently, there are 55.54 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 49.4, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 33.1. The price-earnings ratio gauges market expectation of future performance by relating a stock ...Nov 15, 2023 · On November 14, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $153.79 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 7.92%, and its shares lost 19.47% of their ... Repligen Corporation (NasdaqGS:RGEN) completed the acquisition of Bio-Flex Solutions, L.L.C. / Newton T & M Corp for $31.8 million on December 16, 2021. The purchase price of $31.8 million includes $3 million deposited into an escrow against which the Company may make claims for indemnification.Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of …Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.11.55%. Overview. Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Get Repligen Corp (RGEN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsRepligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price. Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%.Avantor Inc does not currently pay a dividend. Currently, Repligen Corp’s price-earnings ratio is 63.2. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.748 per share for the current fiscal ...Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing ...Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments.Item 1.01 Entry into a Material Definitive Agreement. On March 4, 2022, Repligen Corporation (the "Company") entered into the Second Supplemental Indenture (the "Second Supplemental Indenture") to the Base Indenture, dated July 19, 2019, as supplemented by that certain First Supplemental Indenture thereto, dated July 19, 2019 …Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today.First quarter 2021 adjusted EPS increased to $0.68 per fully diluted share, compared to $0.32 in the 2020 period, an increase of $0.37, or 116%. Cash and cash equivalents, which are GAAP metrics ...The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze. The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics. The number ranges from 0 to 100, with higher numbers indicating ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Financial Details for the Fourth Quarter and Full Year 2021. Total revenue for the fourth quarter of 2021 increased to $186.5 million compared to $108.6 million for the fourth quarter of 2020, a year-over-year gain of 72% as reported and 73% at constant currency, with organic growth of 69%. Total revenue for the full year 2021 increased to …Nov 15, 2023 · On November 14, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $153.79 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 7.92%, and its shares lost 19.47% of their ... However, Repligen stock has ramped up nearly 33% in the aftermath, slightly outperforming even a bullish 30% gain for its medical products peers. Janney analyst Paul Knight expects the company to ...Dec 1, 2023 · See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 48.1. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. The company is headquartered in Waltham, Massachusetts and currently employs 2,025 full-time employees.... Stock quotes by finanzen.net · Home · Stocks · Repligen-stock · News for Repligen Repligen. News for Repligen Corp. GlobeNewswire 20d. UPDATE – Repligen ...Repligen Corporation (NasdaqGS:RGEN) completed the acquisition of Bio-Flex Solutions, L.L.C. / Newton T & M Corp for $31.8 million on December 16, 2021. The purchase price of $31.8 million includes $3 million deposited into an escrow against which the Company may make claims for indemnification.× Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGERepligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.Repligen Corp stock has a Value Score of 6, Growth Score of 82 and Estimate Revisions Score of 38. Comparing West Pharmaceutical Services Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset …Nov 1, 2023 · The stock price rose by $0.27, resulting in a percentage change of +0.61%. While this may seem like a small change, it indicates positive momentum for the company’s stock. Looking ahead, Repligen Corporation is scheduled to release its next financial report on February 15, 2024. When you start a small business, you’ll have many decisions to make. The process involves everything from choosing a business model and designing your marketing materials to hiring employees and setting prices.Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens; A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas; AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount; Dividend Investing Newsletter and model …A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 20.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%.Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Company Info. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs.Jul 21, 2023 · Repligen Corp’s ( RGEN) price is currently up 23.95% so far this month. During the month of July, Repligen Corp’s stock price has reached a high of $177.18 and a low of $134.64. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $134.64. Year to date, Repligen Corp’s stock is down 33.79%. The stock price of Repligen (NASDAQ: RGEN), a U.S.-based life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last ...UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of …Repligen Corporation Common Stock (RGEN) Stock Price, Quote, News & History | Nasdaq MY QUOTES: RGEN Edit my quotes Repligen Corporation Common Stock (RGEN) 0 Add to Watchlist...The stock’s market cap achieved a total value of $6.67 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Repligen Corp. (NASDAQ:RGEN) is 49.48.America’s largest Marine Corps bases include North Carolina’s Marine Corps Base Camp Lejeune, and California’s Marine Corps Air Ground Combat Center Twentynine Palms and Marine Corps Base Camp Pendleton.Apr 21, 2020 · However, Repligen stock has ramped up nearly 33% in the aftermath, slightly outperforming even a bullish 30% gain for its medical products peers. Janney analyst Paul Knight expects the company to ... Nov 9, 2023 · Summary. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. Repligen Corporation to Present at Upcoming Investor Conferences. Nov. 07. AQ. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03. NASDAQ does not use this value to determine compliance with the listing requirements. Repligen Corporation Common Stock (RGEN) Stock Quotes - Nasdaq offers stock quotes & market activity data for ...www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2] Get Repligen Corp (RGEN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsHowever, Repligen stock has ramped up nearly 33% in the aftermath, slightly outperforming even a bullish 30% gain for its medical products peers. Janney analyst Paul Knight expects the company to ...Repligen Corp Stock Price History. Repligen Corp’s price is currently up 12.18% so far this month. During the month of November, Repligen Corp’s stock price has reached a high of $152.22 and a low of $126.86. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $110.45. Year to date, Repligen Corp’s stock is ...11 brokers have issued 12-month price targets for Repligen's stock. Their RGEN share price targets range from $165.00 to $210.00. On average, they expect the company's share price to reach $189.55 in the next year. This suggests a possible upside of 19.5% from the stock's current price. Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the ...Repligen Corp Stock Price History. Repligen Corp’s price is currently down 21.75% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $124.12. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $134.64. Year to date, Repligen Corp’s stock is ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 5.92% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.8. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 19.9% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%.... shares relative to the market in the next few months. In addition, Repligen Corporation has a VGM Score of F (this is a weighted average of the individual ...See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 47.0. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 81.2. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Currently, there are 55.71 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 65.7, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 37.9. The price-earnings ratio gauges market expectation of future performance by relating a stock ...Die Repligen Corp. Aktie wird unter der ISIN US7599161095 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, NASDAQ, Bats, BX World, NASDAQ Bsc, Gettex, Tradegate, Lang & Schwarz ...In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%. Financial Statements.On November 1, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN had a median target of $190.00, with a high estimate of $210.00 and a low estimate of $148.00. This median estimate represents a significant increase of …RGEN stock, belonging to Repligen Corp, has shown promising performance on October 31, 2023, based on the information provided. The data source for this analysis is CNN Money. According to the 13 analysts, the median target price for Repligen Corp is $195.00. The high estimate is $240.00, while the low estimate stands …Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing ...4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Nov 15, 2023 · On November 14, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $153.79 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 7.92%, and its shares lost 19.47% of their ... Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. View Repligen Corporation RGEN investment & stock information. Get the latest Repligen Corporation RGEN detailed stock quotes, stock data, Real-Time ECN, ...Dec 1, 2023 · See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Dec 2, 2023 · With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of $0.78 in Dec 31, 1997 . If you had invested in Repligen stock at $0.78 , your return over the last 25 years would have been 21,019.08% , for an annualized return of 23.88% (not ... Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Stocks of Repligen Corp. saw a sharp rise in short interest on Nov 14, 2023 jumping by 10000.0 shares to 5.99 million. Data from Yahoo Finance shows that the short interest on Oct 12, 2023 was 5.98 million shares. A jump of 0.17% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just ...On average, Wall Street analysts predict. that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a potential upside of 25.33% from the current RGEN share price of $150.60.Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Jul 21, 2023 · Repligen Corp’s ( RGEN) price is currently up 23.95% so far this month. During the month of July, Repligen Corp’s stock price has reached a high of $177.18 and a low of $134.64. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $134.64. Year to date, Repligen Corp’s stock is down 33.79%. Repligen corp stock

As of February 22, 2023, Repligen Corp had a $9.9 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $330.1 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 5.92% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.8.. Repligen corp stock

repligen corp stock

Listed in 1986. repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp Stock Price History. Repligen Corp’s price is currently down 7.01% so far this month. During the month of September, Repligen Corp’s stock price has reached a high of $179.27 and a low of $156.92. Over the last year, Repligen Corp has hit prices as high as $225.62 and as low as $134.64. Year to date, Repligen Corp’s stock is ...Oct 30, 2023 · Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%. Oct 9, 2023 · With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ... Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.4 thg 4, 2016 ... Once you've won approval for a biologic, or biosimilar, manufactured at a particular facility, you can't just switch to another without jumping ...Stock analysis for Repligen Corp (RGEN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Feb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%. Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock...Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens; A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas; AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount; Dividend Investing Newsletter and model …Nov 30, 2023 · The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares. Repligen Corp’s ( RGEN) price is currently down 28.2% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $110.45. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $118.08. Year to date, Repligen Corp’s stock is down 56.89%.RGEN Repligen Corp. 161.78 1.57 ( 0.98%) Market Closed Delayed Prices By NASDAQ, in USD. Trade. Overview Chart Analysis News Stats.Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Delivers base business growth of 29% for the quarter Expands Process Analytics portfolio with DRS Daylight Solutions agreement WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - …UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of …Find the latest Repligen Corporation (RGN.F) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Repligen Corporation (NASDAQ:RGEN) Q3 ...Oct 25, 2023 · Repligen Corp Stock Price History. Repligen Corp’s price is currently down 21.75% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $124.12. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $134.64. Year to date, Repligen Corp’s stock is ... Repligen - RGEN - Stock Price Today - Zacks Repligen (RGEN) (Delayed Data from NSDQ) $164.94 USD +7.69 (4.89%) Updated Dec 1, 2023 04:00 PM ET After-Market: $161.40 -3.54 (-2.15%) 7:58 PM ET...Mar 8, 2023 · Repligen Corp’s ( RGEN) price is currently up 0.21% so far this month. During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $171.57. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.02%. 4.08%. $2.65B. CureVac N.V. 1.85%. $1.21B. RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2] Repligen Corporation (NasdaqGS:RGEN) completed the acquisition of Bio-Flex Solutions, L.L.C. / Newton T & M Corp for $31.8 million on December 16, 2021. The purchase price of $31.8 million includes $3 million deposited into an escrow against which the Company may make claims for indemnification.Repligen Corp’s Stock Price as of Market Close. As of March 03, 2023, 4:00 PM CST, Repligen Corp’s stock price was $188.00. Repligen Corp is up 4.17% from its previous closing price of $180.48. During the last market session, Repligen Corp’s stock traded between $171.57 and $184.29.Mar 27, 2023 · During the month of March, Repligen Corp’s stock price has reached a high of $189.87 and a low of $157.11. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 36.92%. Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Find the latest Repligen Corp (RGN.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.Successfully navigating the dynamic landscape of stock investing requires an understanding of factors like momentum to judge a stock’s price trend. In this article, we take an in-depth look at Repligen Corp (RGEN) to unravel why momentum evaluation plays a crucial role in making savvy investment choices. We also examine how to measure ...See Insiders’ Hot Stocks on TipRanks >> Based on Repligen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $182.66 million and a net ...Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 48.1. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. Analysts expect adjusted earnings to reach $2.678 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare DexCom, Inc. and Repligen Corp Stock ...Find the latest Repligen Corporation (RGN.F) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Repligen Corporation (NASDAQ:RGEN) Q3 ...Repligen Corporation. Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million. Narrows full year revenue guidance to range of $635-$645 million ...In a report released today, Puneet Souda from SVB Securities maintained a Buy rating on Repligen (RGEN – Research Report), with a price target of $200.00.The company’s shares opened today at ...305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Oct 31, 2023 · WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for ... Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 35 and Quality Score of 70. Comparing Adapthealth Corp and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. ... Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ ...Dec 1, 2023 · See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions. What is Repligen Corp(RGEN)'s stock price today? The current price of RGEN is $160.21. The 52 week high of RGEN is $200.98 and 52 week low is $110.45. When is ...Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.A high-level overview of Repligen Corporation (RGEN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Repligen Corp. analyst ratings, historical stock prices, earnings estimates & actuals. RGEN updated stock price target summary.Nov 24, 2023 · In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%. Financial Statements. Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock...Repligen Corporation stock price live 159.46, this page displays NASDAQ RGEN stock exchange data. View the RGEN premarket stock price ahead of the market session or assess the after hours quote.RGN:MUN Munich Stock Exchange; RGN:STU Stuttgart Stock Exchange; RGEN:DEU German Composite; RGN:FRA Frankfurt Stock Exchange; RGN:DUS Dusseldorf Stock Exchange; ... Repligen Corp BUILDING 1, SUITE 100, 41 SEYON STREET WALTHAM 02453 United States USA; Phone +1 (781) 449-9560; Fax +1 (302) …Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens; A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas; AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount; Dividend Investing Newsletter and model …. Stocks at 52 week low today